Fingolimod induced fulminant liver failure requiring liver  transplantation: A case report

ÇALIŞKAN, ALİ RIZA; Samdanci, Emine; CIRIK, SALİH; Harputluoglu, Murat; Yilmaz, Sezai

doi:10.14744/hf.2022.2022.0033

Fingolimod induced fulminant liver failure requiring liver transplantation: A case report

Ali Rıza ÇALIŞKAN, (Marmara Üniversitesi, Tıp Fakültesi, Gastroenteroloji Anabilim Dalı, İstanbul, Türkiye)

Muhsin Murat HARPUTLUOĞLU, (Marmara Üniversitesi, Tıp Fakültesi, İstanbul, Türkiye)

Emine TÜRKMEN ŞAMDANCI, (Recep Tayyip Erdoğan Üniversitesi, Rize Eğitim ve Araştırma Hastanesi Gastroenteroloji Bölümü, Rize, Türkiye)

SALİH CIRIK, (Marmara Üniversitesi, Gastroenteroloji Enstitüsü, İstanbul, Türkiye)

Sezai YILMAZ (Recep Tayyip Erdoğan Üniversitesi, Gastroenteroloji Anabilim Dalı, Tıp Fakültesi, Rize, Türkiye)

Hepatology forum

4 0

Yıl: 2023 Cilt: 4 Sayı: 2 Sayfa Aralığı: 74 - 77 Metin Dili: İngilizce DOI: 10.14744/hf.2022.2022.0033 İndeks Tarihi: 03-06-2023

Fingolimod induced fulminant liver failure requiring liver transplantation: A case report

Öz:

Fingolimod has been used for about ten years to treat multiple recurrent sclerosis. It has been reported that Fingolimod causes an elevation in liver enzymes. In this case report, the clinical and laboratory parameters im proved after discontinuation of the drug. However, there is no publication in the literature regarding acute liver failure and liver transplantation fol lowing Fingolimod treatment. In this article, we presented a 33 – year – old female patient who developed acute liver failure and underwent liver transplantation after Fingolimod treatment for recurrent multiple sclerosis.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Olgu Sunumu Erişim Türü: Erişime Açık

1. Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology 2012;55(3):965-967.
2. Lee WM, Squires Jr RH, Nyberg SL, Doo E, Hoofnagle JH. Acute liver failure: summary of a workshop. Hepatology 2008;47(4):1401-1415.
3. Lee WM. Etiologies of acute liver failure. Semin Liver Dis 2008;28(2):142- 152.
4. Hofmann M, Brinkmann V, Zerwes HG. FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs. Int Immunopharmacol 2006;6(13-14):1902-1910.
5. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immu nol 2005;23:683-747.
6. Tullman MJ. Overview of the epidemiology, diagnosis, and disease progres sion associated with multiple sclerosis. Am J Manag Care 2013;19(Suppl 2):S15-S20.
7. World Health Organization. WHO pharmaceuticals newsletter: 2021, No 1. WHO pharmaceuticals newsletter. Geneva: Worl Health Organization; 2021;(1):1-37.
8. Faissner S, Gold R. Efficacy and safety of the newer multiple sclerosis drugs approved since 2010. CNS Drugs 2018;32(3):269-287.
9. Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, et al; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362(5):387-401.
10. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al; TRANSFORMS Study Group. Oral fingolimod or intramuscular in terferon for relapsing multiple sclerosis. N Engl J Med 2010;362(5):402- 415.
11. Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, place bo-controlled, phase 3 trial. Lancet Neurol 2014;13(6):545-556.
12. Kappos L, Cohen J, Collins W, de Vera A, Zhang-Auberson L, Ritter S, et al. Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings. Mult Scler Relat Disord 2014;3(4):494-504.
13. Cohen JA, Khatri B, Barkhof F, Comi G, Hartung HP, Montalban X, et al. Long-term (up to 4.5 years) treatment with Fingolimod in multiple Sclero sis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry 2016;87(5):468-475.
14. Yamout BI, Zeineddine MM, Tamim H, Khoury SJ. Safety and efficacy of Fingolimod in clinical practice: The experience of an academic center in the Middle East. J Neuroimmunol 2015;289:93-97.
15. Antonazzo IC, Poluzzi E, Forcesi E, Riise T, Bjornevik K, Baldin E, et al. Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System. Mult Scler 2019;25(12):1633- 1640.
16. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
17. Lu MC, Shih YL, Hsieh TY, Lin JC. Flare of hepatitis B virus after fingoli mod treatment for relapsing and remitting multiple sclerosis. J Formos Med Assoc 2020;119(4):886-887.

APA	ÇALIŞKAN A, Harputluoglu M, Samdanci E, CIRIK S, Yilmaz S (2023). Fingolimod induced fulminant liver failure requiring liver transplantation: A case report. , 74 - 77. 10.14744/hf.2022.2022.0033
Chicago	ÇALIŞKAN ALİ RIZA,Harputluoglu Murat,Samdanci Emine,CIRIK SALİH,Yilmaz Sezai Fingolimod induced fulminant liver failure requiring liver transplantation: A case report. (2023): 74 - 77. 10.14744/hf.2022.2022.0033
MLA	ÇALIŞKAN ALİ RIZA,Harputluoglu Murat,Samdanci Emine,CIRIK SALİH,Yilmaz Sezai Fingolimod induced fulminant liver failure requiring liver transplantation: A case report. , 2023, ss.74 - 77. 10.14744/hf.2022.2022.0033
AMA	ÇALIŞKAN A,Harputluoglu M,Samdanci E,CIRIK S,Yilmaz S Fingolimod induced fulminant liver failure requiring liver transplantation: A case report. . 2023; 74 - 77. 10.14744/hf.2022.2022.0033
Vancouver	ÇALIŞKAN A,Harputluoglu M,Samdanci E,CIRIK S,Yilmaz S Fingolimod induced fulminant liver failure requiring liver transplantation: A case report. . 2023; 74 - 77. 10.14744/hf.2022.2022.0033
IEEE	ÇALIŞKAN A,Harputluoglu M,Samdanci E,CIRIK S,Yilmaz S "Fingolimod induced fulminant liver failure requiring liver transplantation: A case report." , ss.74 - 77, 2023. 10.14744/hf.2022.2022.0033
ISNAD	ÇALIŞKAN, ALİ RIZA vd. "Fingolimod induced fulminant liver failure requiring liver transplantation: A case report". (2023), 74-77. https://doi.org/10.14744/hf.2022.2022.0033

APA	ÇALIŞKAN A, Harputluoglu M, Samdanci E, CIRIK S, Yilmaz S (2023). Fingolimod induced fulminant liver failure requiring liver transplantation: A case report. Hepatology forum, 4(2), 74 - 77. 10.14744/hf.2022.2022.0033
Chicago	ÇALIŞKAN ALİ RIZA,Harputluoglu Murat,Samdanci Emine,CIRIK SALİH,Yilmaz Sezai Fingolimod induced fulminant liver failure requiring liver transplantation: A case report. Hepatology forum 4, no.2 (2023): 74 - 77. 10.14744/hf.2022.2022.0033
MLA	ÇALIŞKAN ALİ RIZA,Harputluoglu Murat,Samdanci Emine,CIRIK SALİH,Yilmaz Sezai Fingolimod induced fulminant liver failure requiring liver transplantation: A case report. Hepatology forum, vol.4, no.2, 2023, ss.74 - 77. 10.14744/hf.2022.2022.0033
AMA	ÇALIŞKAN A,Harputluoglu M,Samdanci E,CIRIK S,Yilmaz S Fingolimod induced fulminant liver failure requiring liver transplantation: A case report. Hepatology forum. 2023; 4(2): 74 - 77. 10.14744/hf.2022.2022.0033
Vancouver	ÇALIŞKAN A,Harputluoglu M,Samdanci E,CIRIK S,Yilmaz S Fingolimod induced fulminant liver failure requiring liver transplantation: A case report. Hepatology forum. 2023; 4(2): 74 - 77. 10.14744/hf.2022.2022.0033
IEEE	ÇALIŞKAN A,Harputluoglu M,Samdanci E,CIRIK S,Yilmaz S "Fingolimod induced fulminant liver failure requiring liver transplantation: A case report." Hepatology forum, 4, ss.74 - 77, 2023. 10.14744/hf.2022.2022.0033
ISNAD	ÇALIŞKAN, ALİ RIZA vd. "Fingolimod induced fulminant liver failure requiring liver transplantation: A case report". Hepatology forum 4/2 (2023), 74-77. https://doi.org/10.14744/hf.2022.2022.0033